About / Founder
25 years of medical device experience.
One conviction: close the loop.
Who is building Somnus Technologies?
Matthew Cronin, Founder & CEO, brings 25 years of medical device experience to building the closed-loop infrastructure layer for upper airway dysfunction. Clinical Advisor Dr. Agustin J. Arrieta, MD (Otolaryngology / Sleep Medicine, South Florida ENT Associates) sees the unmet need firsthand in active clinical practice.
Matthew Cronin
Founder & CEO, Somnus Technologies, Inc.
Matt Cronin founded Somnus Technologies after 25 years working inside medical device companies, close enough to patients and providers to see the same problem repeat: the tools to address upper airway dysfunction existed in fragments, and nobody was building the system to connect them.
His conviction: stay lean, stay close to patients and providers, own the loop. Don't become a company where care decisions are made by people who've never met a patient.
Partners and providers are bought in. The advisory table has met patients. The regulatory approach is deliberate. The build is staged so each stage de-risks the next.
Book a callWe power every decision with AI.
This is who we are.
We’re building the closed-loop data network for upper airway care, connecting every signal so no patient is lost to a handoff, and making the whole system smarter and more affordable as it grows. We intend to set the standard. Not the loudest, not the first to ship a gadget: the best at the thing that actually matters, and proving it with clinical efficacy rather than claiming it.
We respect expertise. We tell the truth about what’s built and what isn’t. We earn trust the slow way, because it’s the only way that holds.
You don’t have to agree with how we work. But if you do (if you want the best solution, done the right way), there’s a place for you here.
"On any full clinic day, I see three to five patients presenting with snoring and mild sleep apnea concerns, sometimes more. The demand for a single-procedure palatal solution is steady and underserved by today's options."
Advisors & Counsel
Matthew Cronin
Founder & CEO, Somnus Technologies, Inc.
Dr. Agustin J. Arrieta, MD
Clinical Advisor: Otolaryngology / Sleep Medicine,
South Florida ENT Associates
Mike Kremkau
Industry veteran, strategic advisor.
John R. McDonald
Corporate counsel, Shareholder at Godfrey & Kahn
Corporate, financing.
Amy Salmela
Patent counsel, Partner at EIP
Patent prosecution, USPTO assignments, freedom-to-operate.
Jeffrey K. Shapiro
FDA counsel, Partner at King & Spalding
FDA Life Sciences · 510(k) · General Wellness Policy.
Questions about Somnus Technologies and upper airway dysfunction
- What is upper airway dysfunction (UAD)?
- Upper airway dysfunction (UAD) covers conditions involving obstruction or collapse of the upper airway during breathing, most commonly associated with snoring and obstructive sleep apnea. An estimated 84 million US adults have OSA (32.4% prevalence, 2024);1 approximately 80% (68.5 million of 85.6 million) remain undiagnosed.2 Snoring is the most common early sign of OSA.
- What is HYPNARA™ and how does it work?
- HYPNARA™ is a passive structural palatal implant designed to be placed in a ~20-minute, office-based procedure under local anesthesia. The porous-ingrowth implant reinforces the soft palate. No hospital. No general anesthesia. HYPNARA™ is not yet FDA cleared and not yet available for sale. A safety-and-effectiveness clinical study is required; CRO selection is in final evaluation.
- What is the Somnus Index™?
- The Somnus Index™ is a wellness metric (a breathing credit score) tracking progression across the Somnus platform. It is positioned under the FDA General Wellness Policy. Somnus Index™ is a wellness metric; it is not a medical device.
- How is Somnus different from CPAP or surgery?
- Somnus focuses on mask-free, ultra-minimally invasive solutions for upper airway dysfunction. HYPNARA™ is a one-time in-office procedure. No nightly equipment, no hospital admission. MORPHEX™AI is a smart oral device with on-device analytics. Together with Nightsong™ and the Somnus Index™, these components form a closed-loop system that senses, scores, routes, treats, and learns.
- What conditions is Somnus developing solutions for?
- Somnus Technologies is developing solutions for upper airway dysfunction (UAD), including snoring and mild-to-moderate obstructive sleep apnea in appropriately selected patients.
Talk to Matt directly.
Clinicians, investors, and builders: book a call.
Book a callOr reach us at [email protected]
1 Sönmez et al., Respiratory Medicine 2025;248:108348. DOI: 10.1016/j.rmed.2025.108348. 84 million US adults with OSA; 32.4% prevalence (2024 data).
2 Sönmez et al., Sleep 2025;48(Suppl_1):A278. 68.5 M of 85.6 M US OSA adults undiagnosed (80%).